课题基金 / 基金详情

项目摘要

项目成果

JULIE CHAO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The objective of this application is to investigate the role of kallistatin in protection against cardiac injury induced by hypertension and ischemic heart disease. Kallistatin was discovered, purified and cloned in our laboratory as a specific tissue kallikrein-binding protein and a unique serine proteinase inhibitor. Purified kallistatin is a potent new vasodilator as it directly induces vasorelaxation and reduces blood pressure independent of its kallikrein inhibitory activity. Transgenic mice overexpressing kallistatin are hypotensive, and kallistatin gene delivery in hypertensive rats causes a prolonged reduction of blood pressure. Furthermore, circulating kallistatin levels are markedly reduced in animal models of hypertension, cardiac and renal dysfunction associated with increased inflammation and oxidative stress. These findings suggest a potential role of kallistatin in inflammation-related hypertension and cardiovascular disease. Our recent studies showed that kallistatin gene transfer reduced inflammatory cytokines and joint swelling in collagen-induced arthritis, and reduced inflammatory cell infiltration and apoptosis in the ischemic heart after ischemia/reperfusion (I/R). Based on these new findings, we hypothesize that kallistatin protects against hypertension and ischemic heart disease by inhibiting oxidative stress, inflammation and cardiomyocyte apoptosis. In order to test this hypothesis, we will pursue the following specific aims: 1) to determine the structural elements of kallistatin required for inhibiting inflammation and cardiomyocyte apoptosis after myocardial I/R, 2) to determine the signaling pathways mediated by kallistatin in inhibiting inflammation after myocardial I/R, 3) to determine the signaling pathways mediated by kallistatin in inhibiting apoptosis after myocardial I/R, and 4) to determine the protective role of endogenous kallistatin in hypertension and ischemic heart disease using kallistatin knockout mice and kallistatin knockdown rats by RNA interference. This research proposal should provide significant insights into the role and regulatory mechanisms of kallistatin in the cardiovascular system, and foster the development of therapeutic agents for halting inflammation-related hypertension and ischemic heart disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Kallistatin in Vascular Injury
Kallistatin in Vascular Injury
Kallistatin in Vascular Injury
Regulation and Function of Tissue Kallikrein
国内基金
海外基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    谢文晖
  • 依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
  • 批准号:
    82371726
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    李文
  • 依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
  • 批准号:
    32070790
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    徐小燕
  • 依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈凌
  • 依托单位: